Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.

Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE.

Am J Surg Pathol. 2006 Feb;30(2):216-22.

PMID:
16434896
2.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

3.

[BRAF initiating mutations in the papillary thyroid carcinoma].

Rusinek D, Gubała E.

Endokrynol Pol. 2006 Jul-Aug;57(4):438-44. Review. Polish.

PMID:
17006850
4.

Clinical prognosis in BRAF-mutated PTC.

Puxeddu E, Moretti S.

Arq Bras Endocrinol Metabol. 2007 Jul;51(5):736-47. Review.

5.

Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature.

Rossi S, Fugazzola L, De Pasquale L, Braidotti P, Cirello V, Beck-Peccoz P, Bosari S, Bastagli A.

Endocr Relat Cancer. 2005 Jun;12(2):281-9. Review.

6.

BRAF mutations in papillary thyroid carcinoma.

Wojciechowska K, Lewinski A.

Endocr Regul. 2006 Dec;40(4):129-38. Review.

PMID:
17201587
7.

[The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].

Zafon C, Obiols G.

Endocrinol Nutr. 2009 Apr;56(4):176-86. doi: 10.1016/S1575-0922(09)70982-9. Review. Spanish.

PMID:
19627734
8.

[BRAF gene mutation in thyroid cancer].

Kopczyńska E, Junik R, Tyrakowski T.

Pol Merkur Lekarski. 2006 Feb;20(116):210-3. Review. Polish.

PMID:
16708643
9.

Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications.

Lassalle S, Hofman V, Ilie M, Butori C, Bozec A, Santini J, Vielh P, Hofman P.

Curr Med Chem. 2010;17(17):1839-50. Review.

PMID:
20345340
11.

Alterations of the BRAF gene in thyroid tumors.

Ciampi R, Nikiforov YE.

Endocr Pathol. 2005 Fall;16(3):163-72. Review.

PMID:
16299399
12.

BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.

Tang KT, Lee CH.

J Chin Med Assoc. 2010 Mar;73(3):113-28. doi: 10.1016/S1726-4901(10)70025-3. Review.

13.

RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.

Ciampi R, Nikiforov YE.

Endocrinology. 2007 Mar;148(3):936-41. Review.

PMID:
16946010
14.

How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer.

Couto JP, Prazeres H, Castro P, Lima J, Máximo V, Soares P, Sobrinho-Simões M.

J Clin Pathol. 2009 May;62(5):414-21. doi: 10.1136/jcp.2008.055343. Review.

PMID:
19147628
15.

Molecular diagnostics of thyroid tumors.

Nikiforov YE.

Arch Pathol Lab Med. 2011 May;135(5):569-77. doi: 10.1043/2010-0664-RAIR.1. Review.

PMID:
21526955
16.

Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.

Nikiforova MN, Nikiforov YE.

Expert Rev Mol Diagn. 2008 Jan;8(1):83-95. Review.

PMID:
18088233
17.
18.
19.

[BRAF gene mutation in the natural history of papillary thyroid carcinoma: diagnostic and prognostic implications].

Lopes JP, Fonseca E.

Acta Med Port. 2011 Dec;24 Suppl 4:855-68. Review. Portuguese.

20.

Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions.

Handkiewicz-Junak D, Czarniecka A, Jarzab B.

Mol Cell Endocrinol. 2010 Jun 30;322(1-2):8-28. doi: 10.1016/j.mce.2010.01.007. Review.

PMID:
20138116
Items per page

Supplemental Content

Support Center